Sagimet Biosciences Inc. (SGMT) has an important upcoming event this month concerning its lead investigational asset, Denifanstat.
Denifanstat is an oral, once-daily pill and selective FASN inhibitor, which successfully completed a phase IIb trial in biopsy-confirmed Metabolic dysfunction-associated steatohepatitis (MASH) patients with moderate-to-severe fibrosis in January of this year.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com